The ReSVinet Score for Bronchiolitis: A Scale for All Seasons

Antonio José Justicia-Grande; Federico Martinón-Torres

doi:10.1055/s-0039-1691800

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2019; 36(S 02): S48-S53
DOI: 10.1055/s-0039-1691800

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The ReSVinet Score for Bronchiolitis: A Scale for All Seasons

Antonio José Justicia-Grande

¹GENVIP Group (Genética, Vacunas, Infecciones y Pediatría), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain

²Translational Paediatrics and Infectious Diseases Unit, Department of Paediatrics. Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain

,

Federico Martinón-Torres

¹GENVIP Group (Genética, Vacunas, Infecciones y Pediatría), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain

²Translational Paediatrics and Infectious Diseases Unit, Department of Paediatrics. Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain

› Institutsangaben

Abstract

The ReSVinet Scale is a clinical score for the assessment of respiratory difficulty in infancy. Our aim was to provide an update on the characteristics that make this tool different to any other. We descriptively compared the characteristics of the ReSVinet Scale with other options that can be found in the current literature or mobile apps stores. The ReSVinet Scale has been devised for its use regardless of the age of the child, entity causing respiratory symptoms, and setting. To this date, it is the only pediatric respiratory scale for acute respiratory distress that provides a parental version, and it is also the first one to have undergone validation in primary care. The tool can be found either in paper format or can be downloaded via App stores for devices running on Android or iOS systems. It has also been adopted recently as the assessment instrument for several clinical trials and for an IMI2 initiative (RESCEU project). All the aforementioned characteristics of the ReSVinet Scale should help toward its dissemination, as currently no other clinical tool for the assessment of respiratory difficulty can offer those advantages.

Keywords

clinical scale - respiratory difficulty - validation - wheezing - asthma - bronchiolitis - mHealth intervention

Volltext

Referenzen

References
1 Al-Durra M, Torio MB, Cafazzo JA. The use of behavior change theory in Internet-based asthma self-management interventions: a systematic review. J Med Internet Res 2015; 17 (04) e89
2 Justicia-Grande AJ, Pardo Seco J, Rivero Calle I, Martinón-Torres F. Clinical respiratory scales: which one should we use?. Expert Rev Respir Med 2017; 11 (12) 925-943
3 Bekhof J, Reimink R, Brand PL. Systematic review: insufficient validation of clinical scores for the assessment of acute dyspnoea in wheezing children. Paediatr Respir Rev 2014; 15 (01) 98-112
4 Justicia-Grande AJ, Pardo-Seco J, Cebey-López M. , et al; Respiratory Syncytial Virus network (ReSVinet). Development and validation of a new clinical scale for infants with acute respiratory infection: the ReSVinet scale. PLoS One 2016; 11 (06) e0157665
5 eHealth. WHOGOF. New Horizons for Health through Mobile Technologies. Geneva: World Health Organization; 2011
6 Turner-McGrievy GM, Hales SB, Schoffman DE. , et al. Choosing between responsive-design websites versus mobile apps for your mobile behavioral intervention: presenting four case studies. Transl Behav Med 2017; 7 (02) 224-232
7 Bierbrier R, Lo V, Wu RC. Evaluation of the accuracy of smartphone medical calculation apps. J Med Internet Res 2014; 16 (02) e32
8 Huckvale K, Morrison C, Ouyang J, Ghaghda A, Car J. The evolution of mobile apps for asthma: an updated systematic assessment of content and tools. BMC Med 2015; 13: 58 . Doi: 10.1186/s12916-015-0303-x
9 Musgrove Park Hospital. P.O.P.S. 2016 . Available at Google Play - https://play.google.com/store/apps/details?id=uk.nhs.musgroveparkhospital.pops and App Store - https://itunes.apple.com/hn/app/p-o-p-s/id1181419115?mt=8
10 Roland D, Arshad F, Coats T, Davies F. Baseline characteristics of the paediatric observation priority score in emergency departments outside its centre of derivation. BioMed Res Int 2017; 2017: 9060852
11 Musgrove Park Hospital. Handi Pediatric. 2018 –Available at Google Play (v 2.8.2) - https://play.google.com/store/apps/details?id=com.myoxygen.handi.taunton And AppStore - https://itunes.apple.com/gb/app/handi-paediatric/id969445171?mt=8
12 Gradiant. The ReSVinet Scale App. 2019 . Available at Google Play (v 1.3.8). Available at: ( https://play.google.com/store/apps/details?id=org.ejkc.resvinet&hl=en_US ) and AppStore ( https://itunes.apple.com/us/app/resvinet-score/id1284710379?mt=8
13 Marcano Belisario JS, Jamsek J, Huckvale K, O'Donoghue J, Morrison CP, Car J. Comparison of self-administered survey questionnaire responses collected using mobile apps versus other methods. Cochrane Database Syst Rev. 2015MR000042
14 A Study to determine the epidemiology and evaluate the burden of disease in respiratory syncytial virus/human metapneumovirus and influenza A infected hospitalized participants (Adults and Children). Available at: https://clinicaltrials.gov/ct2/show/NCT03574532
15 Understanding RSV: Severe Disease and the Long Term Consequences. Available at: https://clinicaltrials.gov/ct2/show/NCT03756766?term=ReSVinet&rank=2 . Accessed May 30, 2019
16 Ablynx initiates the phase IIb "respire" study of its wholly-owned, first-in-class, inhaled anti-RSV nanobody, ALX-0171, for the treatment of RSV infections in hospitalised infants. Available at: https://www.globenewswire.com/news-release/2017/01/11/905176/0/en/ABLYNX-INITIATES-THE-PHASE-IIb-RESPIRE-STUDY-OF-ITS-WHOLLY-OWNED-FIRST-IN-CLASS-INHALED-ANTI-RSV-NANOBODY-ALX-0171-FOR-THE-TREATMENT-OF-RSV-INFECTIONS-IN-HOSPITALISED-INFANTS.html . Accessed June 7, 2019